[Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005257
Original Title: Axicabtagen-Ciloleucel (DLBCL und PMBCL, ab Drittlinie)
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, B-Cell
  • Biological Products
  • Immunotherapy, Adoptive
  • Antineoplastic Agents, Immunological
  • Receptors, Chimeric Antigen
  • Axicabtagene Ciloleucel
  • Lymphoma – Large B-Cell – Diffuse
  • Benefit Assessment
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.